SV

Street Verdict

Analyst Scorecard

A record of what Motilal Oswal Analysis said publicly, with the source. Not advice.

“Reiterated a 'Buy' rating on Glenmark Pharma, seeing a 28% upside from Thursday’s closing price of ₹1,904, with a 12-month forward earnings multiple leading to a sum-of-the-parts (SOTP) valuation of ₹2,430. The AbbVie deal is seen as signaling a new era for the company.”

Motilal Oswal Analysis’s track record (trackable calls only): 453 graded calls · 95% CI 36–45%

Glenmark Pharmaceuticals LtdBullishCalled 11 Jul 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Motilal Oswal Analysis’s full track record